CRSP - CRISPR Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.553B

Cash

1.768B

Avg Qtr Burn

-85.75M

Short % of Float

17.30%

Insider Ownership

1.38%

Institutional Own.

67.47%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CASGEVY™ (Exagamglogene autotemcel) (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Beta thalessemia Big Mover™ Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CASGEVY™ (Exagamglogene autotemcel) (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) (Exa-cel) Details Sickle cell disease Big Mover™ Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX110 (CD19) Details CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VCTX211 Details Type 1 diabetes	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Exagamglogene autotemcel (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Beta thalessemia	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Exagamglogene autotemcel (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Sickle cell disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX112 (CD19) Details CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VCTX210 Details Type 1 diabetes	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX131 (CD70) Details Cancer, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX130 (CD70) Details Blood cancer, Cancer, T-cell lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX120 (BCMA) Details Multiple myeloma, Blood cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.